Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.E™) Program

Astellas Pharma Inc426 enrolled

Overview

Purpose: To develop a real time national clinical database to support and share best practices, 1. To generate hypotheses for future clinical research 2. To understand how AMEVIVE is used in routine clinical practice/real world setting. Each patient visit will include the following observational endpoints: 1. AMEVIVE dosing 2. Number of courses 3. Concomitant treatment 4. Response to treatment (patient and physician global assessments) 5. Status of other psoriasis-related medical conditions 6. Time to re-treatment.

Study Type

OBSERVATIONAL

Enrollment

426

Conditions

Plaque Psoriasis

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Amevive is clinically indicated for the patient Exclusion Criteria: * Amevive is contraindicated for the patient

Locations (30)

Unnamed facility

Calgary, Alberta, Canada

Outcomes

Primary Outcomes

Understand how AMEVIVE is used in routine clinical practice/real world setting

Time frame: End of study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.